Peter Nieboer

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Renu R. Bahadoer, Esmée A. Dijkstra, Boudewijn van Etten et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Surgery +17

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Lieke H. J. Simkens, Harm van Tinteren, Anne M. May et al. · The Lancet · 2015 · 528 citations

Medicine, Oncology, Pharmacology +13

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer

Annelies H. Boekhout, Jourik A. Gietema, Bojana Milojkovic Kerklaan et al. · JAMA Oncology · 2016 · 199 citations · Full text

Medicine, Oncology, Pharmacology +17

Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study

Peter Nieboer, Ciska Buijs, Sjoerd Rodenhuis et al. · Journal of Clinical Oncology · 2005 · 104 citations · Full text

Medicine, Oncology, Breast Oncology +16